INDIVIOR PHARMACEUTICALS, INC.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$1.20B
↓-8.7% -$115Mvs FY2024
Total Liabilities
$1.30B
↓-21.3% -$352Mvs FY2024
Cash
$195M
↓-38.9% -$124Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $1.20B | $1.32B |
| Current Assets | $652M | $827M |
| Cash | $195M | $319M |
| ST Investments | $0 | $1M |
| Receivables | $253M | $254M |
| Inventory | $153M | $167M |
| Other Current | $51M | $86M |
| Non-Current Assets | $549M | $489M |
| PPE | $144M | $100M |
| Goodwill | $2M | $2M |
| Intangibles | $0 | $0 |
| Investments | $28M | $27M |
| Other Non-Current | $375M | $360M |
| Total Liab+Eq | $1.20B | $1.31B |
| Current Liab. | $914M | $924M |
| Accounts Payable | $48M | $63M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $0 |
| Other CL | $866M | $861M |
| Non-Current Liab. | $386M | $728M |
| Long-Term Debt | $290M | $315M |
| Other LT Liab. | $96M | $413M |
| Equity | $-98M | $-337M |
| Retained Earnings | $243M | $443M |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · INDV · Comparing FY2025 vs FY2024